 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...187188189190191192193194195196197...208209» |
- | AiTan (rivoceranib) / HLB Bio Group
New P3 trial, Metastases: HRA-G04: Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction (clinicaltrials.gov) - Jun 13, 2019
P3, N=180, Not yet recruiting, Sponsor: Hebei Medical University
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Apatinib Plus SHR1210 in Advanced Mucosal Melanoma (clinicaltrials.gov) - Jun 13, 2019
P2, N=40, Recruiting, Sponsor: Henan Cancer Hospital
- | AiTan (rivoceranib) / LSK BioPartners
Clinical, Observational data, Journal: Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study. (Pubmed Central) - Jun 13, 2019
Proteinuria was an independent predictive factor for PFS and OS. Apatinib combined with chemotherapy appeared to be efficacious for pretreated advanced breast cancer, with acceptable toxicity for real-world clinical practice.
- | AiTan (rivoceranib) / LSK BioPartners
Clinical, Journal: Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL-17. (Pubmed Central) - Jun 13, 2019
In addition, apatinib can downregulate IL-17 expression, which is helpful in attenuating tumor proliferation and improving the clinical efficacy. Therefore, apatinib has potential use in a wide range of clinical applications.
- ||| AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Enrollment open: A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer (clinicaltrials.gov) - Jun 13, 2019
P1, N=51, Recruiting, Sponsor: Atridia Pty Ltd.
Therefore, apatinib has potential use in a wide range of clinical applications. Active, not recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer (clinicaltrials.gov) - Jun 11, 2019
P2, N=196, Recruiting, Sponsor: RenJi Hospital
- |||||||||| Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P3 trial: A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer (clinicaltrials.gov) - Jun 11, 2019
P3, N=1192, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||||| Irene (pyrotinib) / Jiangsu Hengrui Pharma
Enrollment closed: Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE) (clinicaltrials.gov) - Jun 7, 2019
P3, N=240, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New P3 trial: Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy. (clinicaltrials.gov) - Jun 5, 2019
P3, N=201, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: FZPL-Ib-105: A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC (clinicaltrials.gov) - Jun 5, 2019
P1, N=52, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New P1 trial: Metabolism and Disposition of [14C] Herombopag in Chinese Healthy Human Subjects (clinicaltrials.gov) - Jun 5, 2019
P1, N=6, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | fluconazole / generics
Journal: Design, synthesis, and structure-activity relationship studies of novel tetrazole antifungal agents with potent activity, broad antifungal spectrum and high selectivity. (Pubmed Central) - Jun 5, 2019
Furthermore, 13k and 13ad were active against Microsporum gypseum, which was resistant to racemic VT-1161. In addition, 13k, 13ac and 13ad, with good in vitro activities against all of pathogenic fungi tested except for Aspergillus fumigatus, had no inhibition of human CYP3A4, suggesting a low risk of drug-drug interactions.
- | camrelizumab (INCSHR1210) / Incyte
Journal: Camrelizumab for nasopharyngeal carcinoma: a new hope? (Pubmed Central) - Jun 5, 2019
In addition, 13k, 13ac and 13ad, with good in vitro activities against all of pathogenic fungi tested except for Aspergillus fumigatus, had no inhibition of human CYP3A4, suggesting a low risk of drug-drug interactions. No abstract available
- ||| DDO-3055 / Jiangsu Hengrui Pharma
New P1 trial: A Study to Evaluate the Safety and Efficacy of DDO-3055 in Healthy Volunteers and Patients With Chronic Kidney Disease (clinicaltrials.gov) - Jun 4, 2019
P1, N=66, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||| pyrotinib (HTI-1001) / Jiangsu Hengrui Medicine
Em pctes com metástases cerebrais, Pyrotinib+Capecitabina também aumenta SLP qndo comparado a Capecitabina no Ca mama metastático HER2+ pós taxano/trast #MOCnaASCO #ASCO19 #bcsm #breastcancer @DGagliato @manoelcarlos_kk @FabioSchutz78 @thiagoonco @camillayamada @RoselyYamamura (Twitter) - Jun 4, 2019
- ||||| pyrotinib (HTI-1001) / Jiangsu Hengrui Medicine, Herceptin (trastuzumab) / Roche
Clinical: Significativo aumento de SLP com Pyrotinib+Capecitabina em relação a Capecitabina+placebo no Ca mama metastático HER2+, previamente tratado com taxano e trastuzumabe Ganho de 7m em SLP (HR 0,18) #MOCnaASCO #ASCO19 #bcsm #breastcancer @DGagliato @manoelcarlos_kk @FabioSchutz78 (Twitter) - Jun 4, 2019
- |||| pyrotinib (HTI-1001) / Jiangsu Hengrui Medicine, Nerlynx (neratinib) / Puma
Carlos Barrios MD take home messages on mergatuximab, pyrotinib, neratinib plus capecitabine #ASCO19 #OncoAlert (Twitter) - Jun 4, 2019
- ||| Kadcyla (ado-trastuzumab emtansine) / Roche, pyrotinib (HTI-1001) / Jiangsu Hengrui Medicine
In places where Kadcyla isn’t available, could pyrotinib + capecitabine be an option for pretreated metastatic HER2+ #breastcancer? #ASCO19 (Twitter) - Jun 4, 2019
- ||||| pyrotinib (HTI-1001) / Jiangsu Hengrui Medicine
Clinical, Monotherapy: Zefei Jiang: PHENIX trial 🔅Pyrotinib plus capecitabine improves PFD vs plac plus capecitabine 🔅parients who progressed on placebo plus capecitabine could benefit from pyrotinib monotherapy #ASCO19 #OncoAlert (Twitter) - Jun 4, 2019
- |||| pyrotinib (HTI-1001) / Jiangsu Hengrui Medicine
Clinical: Jiang pyrotinib plus capecitabine vs cape alone results: PFS increased from 4 to 11 mo, p < .001, HR 0.18, with Increased ORR. Suggestion of benefit in brain met patients, and in prevention of brain mets. (Twitter) - Jun 4, 2019
- ||||| pyrotinib (HTI-1001) / Jiangsu Hengrui Medicine, Herceptin (trastuzumab) / Roche
Clinical, P3 data: ASCO Breast Jiang on pyrotinib plus capecitabine in HER2-pos MBC. Randomized Phase 3 trial. Pyrotinib is an RTKi vs Her 1,2,4. Randomized vs capecitabine alone in pts with prior trastuzumab. PFS as primary endpoint. (Twitter) - Jun 4, 2019
- | AiTan (rivoceranib) / HLB Bio Group
Trial initiation date: Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation (clinicaltrials.gov) - Jun 2, 2019
P2, N=30, Not yet recruiting, Sponsor: First Hospital of Jilin University
No abstract available Initiation date: Nov 2018 --> Jun 2019
- || SHR0532 / Jiangsu Hengrui Pharma
New P1 trial: Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension (clinicaltrials.gov) - Jun 2, 2019
P1, N=36, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||| flumatinib (HHGV-678) / Jiangsu Hengrui Medicine, Jiangsu Hansoh Pharma
#ASCO19 | Dr J Garcia discussant Leukemia session. #FESTnd = #Flumatinib Ph3 results a new TKI compared to imatinib | note different primary endpoint ➡️➡️ MMR at 6 months #leusm (Twitter) - Jun 1, 2019
- ||| flumatinib (HHGV-678) / Jiangsu Hengrui Medicine, Jiangsu Hansoh Pharma
#ASCO19 Liu: flumatinib caused less cytopenias and edema, but more diarrhea than imatinib (mostly low grade) (Twitter) - Jun 1, 2019
- |||| flumatinib (HHGV-678) / Jiangsu Hengrui Medicine, Jiangsu Hansoh Pharma
Clinical: #ASCO19 Liu (for Zhang): Flumatinib, a more Abl-selective TKI, c/w imatinib in randomized fashion (n=196 vs 197), gave higher rate of MMR at all milestones (Twitter) - Jun 1, 2019
- | AiTan (rivoceranib) / LSK BioPartners, Endostar (recombinant human endostatin) / Simcere
Clinical, Journal: Epithelioid hemangioendothelioma of the bone: A case report with findings of bone scintigraphy. (Pubmed Central) - May 31, 2019
EHE of the bone is a very rare malignant vascular neoplasm with no specific radiographic imaging features. Whole-body bone scintigraphy, especially SPECT/CT bone imaging, significantly reduces ambiguous diagnoses and is recommended before treatment.
- | AiTan (rivoceranib) / LSK BioPartners
Clinical, Observational data, Journal: Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study. (Pubmed Central) - May 31, 2019
The main AEs in grade 3 were hypertension, rash, weight loss, hand-foot syndrome, and diarrhea.Apatinib is safe and effective in the treatment of advanced osteosarcoma. We recommend that the initial dose of apatinib should be 500 mg/qd in the treatment of osteosarcoma.
- | camrelizumab (INCSHR1210) / Incyte, Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal: Efficacy of anti-PD-1 antibody SHR-1210 as second-line treatment in hepatocellular carcinoma patient with sorafenib resistance: A case report. (Pubmed Central) - May 30, 2019
We think that SHR-1210 may exert its antitumor effects through a late-onset model, which persist for a long time. The side effects were mild and well tolerated.
- |||||||||| AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New P3 trial: DAWNA-2: A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer (clinicaltrials.gov) - May 28, 2019
P3, N=426, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / LSK BioPartners
Clinical, Journal: The efficacy and safety of apatinib in metastatic alveolar soft part sarcoma: a case series of six patients in one institution. (Pubmed Central) - May 25, 2019
The most common adverse events included gastrointestinal discomfort (4/6[66.7%]), hair hypopigmentation (4/6[66.7%]) and hand-foot skin reaction (3/6[50.0%]). Apatinib shows beneficial activity in metastatic ASPS patients, and further studies are warranted with more cases and longer follow-up periods to fully characterize clinical efficacy and safety of apatinib in ASPS.
- | camrelizumab (INCSHR1210) / Incyte
Journal: Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210. (Pubmed Central) - May 25, 2019
RCHs were prevalent but manageable during treatment with SHR-1210. It might add to the expanding literature regarding immune-related dermatologic adverse events.
- | AiTan (rivoceranib) / LSK BioPartners
Clinical, Journal: Pilot Dose Comparison of Apatinib in Chinese Progressive Radioiodine Refractory Differentiated Thyroid Cancer Patients. (Pubmed Central) - May 24, 2019
However, the occurrence frequency of TAAEs was much higher in 750 mg schedule (26.8±6.5 vs.18.1±6.5 in any grades, P=0.01; 5.2±3.0 vs. 1.6±1.3 in grade ≥3, P<0.01). Within 6 cycles of follow-up, the initial dose of 500 mg protocol might be less toxic than the 750 mg protocol, while the efficacy was similar.
- | AiTan (rivoceranib) / LSK BioPartners
Retrospective data, Journal: Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis [Corrigendum]. (Pubmed Central) - May 23, 2019
Within 6 cycles of follow-up, the initial dose of 500 mg protocol might be less toxic than the 750 mg protocol, while the efficacy was similar. No abstract available
- | AiTan (rivoceranib) / LSK BioPartners, pyrotinib (HTI-1001) / Jiangsu Hengrui Medicine
Journal: Pyrotinib treatment on HER2-positive gastric cancer cells promotes the released exosomes to enhance endothelial cell progression, which can be counteracted by apatinib. (Pubmed Central) - May 23, 2019
Significantly, this effect was counteracted by the vascular endothelial growth factor receptor (VEGFR)-2 inhibitor apatinib which inhibits EC progression. Our study suggests that pyrotinib application on HER2-positive GC produces stronger exosomes that promote the proliferation and motility of vascular ECs, and combination of pyrotinib with apatinib provides potentially better therapy.
- || AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Enrollment closed: OPAL2: A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease (clinicaltrials.gov) - May 23, 2019
P2, N=144, Active, not recruiting, Sponsor: Reistone Biopharma Company Limited
Our study suggests that pyrotinib application on HER2-positive GC produces stronger exosomes that promote the proliferation and motility of vascular ECs, and combination of pyrotinib with apatinib provides potentially better therapy. Recruiting --> Active, not recruiting
- | VT-1161 / Viamet
Clinical, P2 data, Journal: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Orally-Administered VT-1161 in the Treatment of Recurrent Vulvovaginal Candidiasis. (Pubmed Central) - May 22, 2019
In this study, VT-1161 was shown to be efficacious and safe in treating patients with recurrent vulvovaginal candidiasis. These data strongly support further clinical investigation of VT-1161 for the treatment of recurrent vulvovaginal candidiasis.
- | AiTan (rivoceranib) / HLB Bio Group
Trial completion, Combination therapy, Metastases: ARCAP: Apatinib in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment for Symptomatic Metastatic Prostate Cancer (clinicaltrials.gov) - May 21, 2019
P=N/A, N=40, Completed, Sponsor: Sichuan Provincial People's Hospital
These data strongly support further clinical investigation of VT-1161 for the treatment of recurrent vulvovaginal candidiasis. Enrolling by invitation --> Completed
- | AiTan (rivoceranib) / HLB Bio Group
Trial completion date, Trial initiation date, Trial primary completion date: Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC (clinicaltrials.gov) - May 20, 2019
P2, N=90, Not yet recruiting, Sponsor: Hubei Cancer Hospital
Enrolling by invitation --> Completed Trial completion date: Apr 2022 --> Jul 2022 | Initiation date: Apr 2019 --> Jul 2019 | Trial primary completion date: Apr 2020 --> Jul 2020
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: SHR-1210-APTN-IIT-MM: PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma (clinicaltrials.gov) - May 19, 2019
P2, N=30, Recruiting, Sponsor: Beijing Cancer Hospital
- | famitinib (SHR 1020) / Jiangsu Hengrui Medicine
Clinical, P1 data, Journal, Combination therapy: Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study. (Pubmed Central) - May 17, 2019
D-CEUS is a reliable and early measure of efficacy for famitinib therapies. Further investigation is required to confirm the effects of famitinib plus chemoradiotherapy.
- | AiTan (rivoceranib) / LSK BioPartners
Clinical, Journal: Zygomatic bone metastasis from hepatocellular carcinoma and the therapeutic efficacy of apatinib: A case report and literature review. (Pubmed Central) - May 17, 2019
Still now, there is no optimal treatment strategy for these patients. Apatinib may be a promising drug in the treatment of HCC metastases to the zygomatic bone.
- | AiTan (rivoceranib) / LSK BioPartners
Journal: Anti-Colorectal Cancer Effect via Application of Polyethylene Glycol Modified Liposomal Apatinib. (Pubmed Central) - May 16, 2019
The anti-tumor mechanisms included inhibiting tumor proliferation, promoting tumor apoptosis and suppressing tumor angiogenesis. Thereafter, the application of Apatinib-Lipo/PEG would be very promising in colorectal cancer treatment.
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer (clinicaltrials.gov) - May 16, 2019
P2, N=35, Not yet recruiting, Sponsor: Henan Cancer Hospital
- | AiTan (rivoceranib) / LSK BioPartners
Journal: Apatinib exerts anti-tumour effects on ovarian cancer cells. (Pubmed Central) - May 14, 2019
Thereafter, the application of Apatinib-Lipo/PEG would be very promising in colorectal cancer treatment. Based on our findings, apatinib is a highly potent, orally active anti-angiogenic and anti-ovarian cancer agent.
- || AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial: Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer (clinicaltrials.gov) - May 14, 2019
P2, N=30, Recruiting, Sponsor: Beijing Hospital
- | Herceptin (trastuzumab) / Roche, AiRuiKa (camrelizumab) / Elevar Therapeutics
New P2 trial: SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - May 14, 2019
P2, N=25, Not yet recruiting, Sponsor: Henan Cancer Hospital
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New trial: Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer. (clinicaltrials.gov) - May 12, 2019
P=N/A, N=48, Not yet recruiting, Sponsor: Henan Cancer Hospital
- | AiTan (rivoceranib) / LSK BioPartners
Journal: Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway. (Pubmed Central) - May 12, 2019
The anti-tumor effect was mostly due to apatinib induced cell cycle arrest and VEGFR signaling pathway inhibition. These data suggested that apatinib may provide a benefit to patients with acquired resistance to EGFR-TKI treatment.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment change, Trial termination: SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer (clinicaltrials.gov) - May 10, 2019
P2, N=12, Terminated, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
These data suggested that apatinib may provide a benefit to patients with acquired resistance to EGFR-TKI treatment. N=135 --> 12 | Recruiting --> Terminated; The study was terminated early due to company decision